TD Asset Management
MCRB icon

TD Asset Management’s Seres Therapeutics MCRB Stock Holding History

TD Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,086
Closed -$290K – 1521
2021
Q3 		$290K Hold
2,086
– – ﹤0.01% 1454
2021
Q2 		$296K Hold
2,086
– – ﹤0.01% 1445
2021
Q1 		$859K Buy
2,086
+296
+17% +$136K ﹤0.01% 1297
2020
Q4 		$877K Buy
1,790
+225
+14% +$132K ﹤0.01% 1210
2020
Q3 		$886K Buy
+1,565
New +$520K ﹤0.01% 1108
2017
Q2 		– Sell
-759
Closed -$171K – 1354
2017
Q1 		$171K Sell
759
-105
-12% -$21.3K ﹤0.01% 1381
2016
Q4 		$171K Hold
864
– – ﹤0.01% 1350
2016
Q3 		$212K Sell
864
-730
-46% -$256K ﹤0.01% 1361
2016
Q2 		$926K Sell
1,594
-15
-0.9% -$8.8K ﹤0.01% 980
2016
Q1 		$855K Buy
1,609
+864
+116% +$451K ﹤0.01% 994
2015
Q4 		$523K Sell
745
-15
-2% -$9.86K ﹤0.01% 1091
2015
Q3 		$451K Buy
760
+30
+4% +$24.5K ﹤0.01% 1092
2015
Q2 		$606K Buy
+730
New +$637K ﹤0.01% 1071

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TD Asset Management's MCRB Position: Q4 2021 in Review

TD Asset Management sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 2,086 shares — an estimated $290K sold.

TD Asset Management first reported a position in MCRB in Q2 2015 and held it in 13 quarters. The position peaked at $926K in Q2 2016. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • TD Asset Management reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • TD Asset Management sold 2,086 Seres Therapeutics shares in Q4 2021, an estimated $290K.
  • TD Asset Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 13 quarters.
  • TD Asset Management's Seres Therapeutics position peaked at $926K in Q2 2016.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.